Track topics on Twitter Track topics that are important to you
Sunnyvale, May 09, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces receipt of a new clinical licensure from the Centers for Medicare and Medicaid Services (CMS), which oversees the Clinical Laboratory Improvement Amendments (CLIA) Program. Arrayit’s new CLIA license, issued in conjunction with the Department of Health and Human Services (HHS) and the California Department of Public Health (CDPH), provides certification for its Silicon Valley clinical laboratory.
Arrayit has developed patented and proprietary microarray technology, validated through the CLIA program, to measure immunoglobulin E (IgE) and immunoglobulin G (IgG) levels for the purposes of allergy and dietary wellness testing. Arrayit tests employ non-invasive finger stick blood sampling, blood cards and a highly miniaturized and automated microarray format to deliver results accurately and quickly. The company enters the $3.2 trillion US healthcare market by offering its tests to hospitals, health maintenance organizations (HMOs), clinical laboratories, physician groups with patients covered by private and government health insurance, and consumers through the assistance of a medical doctor.
CEO Rene Schena states, “This milestone facilitates our translational medicine initiative, to move Arrayit’s leading-edge technology beyond the research laboratory into the clinic. Our advanced microarray tests possess tremendous promise to improve healthcare based on non-invasive finger stick testing and rapid reporting across multiplexed testing panels, delivering actionable medical information for value-based medicine. Every Arrayit employee contributed to this achievement. What an amazing team we have.”
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the research, biotechnology, pharmaceutical, clinical and healthcare sectors through the discovery, development and manufacture of proprietary life science and personalized medicine products and services to advance biomedical research and improve wellness and human health. Please visit www.arrayit.com for more information.
Safe Harbor Statement
We have identified forward-looking statements by using words such as "expect", "believe", and "should". Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's public filings.
CONTACT Public Relations Arrayit Corporation Tel: 408-744-1331 Email: email@example.com Web: www.arrayit.comNEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...
A DNA microarray or biochip is a collection of microscopic DNA spots attached to a solid surface used to measure the expression levels of large numbers of genes simultaneously or to genotype multiple regions of a genome.